Agnieszka Latosinska
Agnieszka Latosinska
Mosaiques diagnostics GmbH
Bestätigte E-Mail-Adresse bei mosaiques-diagnostics.com
Titel
Zitiert von
Zitiert von
Jahr
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development
M Frantzi, A Bhat, A Latosinska
Clinical and translational medicine 3 (1), 1-22, 2014
1212014
Comparative analysis of label-free and 8-Plex iTRAQ approach for quantitative tissue proteomic analysis
A Latosinska, K Vougas, M Makridakis, J Klein, W Mullen, M Abbas, ...
PloS one 10 (9), e0137048, 2015
842015
Developing proteomic biomarkers for bladder cancer: towards clinical application
M Frantzi, A Latosinska, L Flühe, MC Hupe, E Critselis, MW Kramer, ...
Nature Reviews Urology 12 (6), 317-330, 2015
622015
Proteomics biomarkers for solid tumors: Current status and future prospects
I Belczacka, A Latosinska, J Metzger, D Marx, A Vlahou, H Mischak, ...
Mass spectrometry reviews 38 (1), 49-78, 2019
392019
Proteomics and metabolomics for AKI diagnosis
D Marx, J Metzger, M Pejchinovski, RB Gil, M Frantzi, A Latosinska, ...
Seminars in nephrology 38 (1), 63-87, 2018
372018
Comparison of depletion strategies for the enrichment of low-abundance proteins in urine
S Filip, K Vougas, J Zoidakis, A Latosinska, W Mullen, G Spasovski, ...
PLoS One 10 (7), e0133773, 2015
362015
Peptidomics and proteomics based on CE‐MS as a robust tool in clinical application: The past, the present, and the future
A Latosinska, J Siwy, H Mischak, M Frantzi
Electrophoresis 40 (18-19), 2294-2308, 2019
312019
Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: focus on bladder cancer
A Latosinska, M Frantzi, A Vlahou, H Mischak
Proteomics–Clinical Applications 7 (11-12), 779-793, 2013
302013
Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups
S Siebert, D Porter, C Paterson, R Hampson, D Gaya, A Latosinska, ...
Scientific reports 7 (1), 1-9, 2017
232017
Analytical performance of ELISA assays in urine: one more bottleneck towards biomarker validation and clinical implementation
D Chatziharalambous, V Lygirou, A Latosinska, K Stravodimos, A Vlahou, ...
PloS one 11 (2), e0149471, 2016
232016
Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease
V Lygirou, A Latosinska, M Makridakis, W Mullen, C Delles, JP Schanstra, ...
Journal of translational medicine 16 (1), 1-12, 2018
212018
Clinical proteomics for precision medicine: the bladder cancer case
A Latosinska, M Frantzi, A Vlahou, AS Merseburger, H Mischak
PROTEOMICS–Clinical Applications 12 (2), 1700074, 2018
202018
Urinary CE-MS peptide marker pattern for detection of solid tumors
I Belczacka, A Latosinska, J Siwy, J Metzger, AS Merseburger, H Mischak, ...
Scientific reports 8 (1), 1-11, 2018
192018
Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention
A Latosinska, M Mokou, M Makridakis, W Mullen, J Zoidakis, V Lygirou, ...
Oncotarget 8 (41), 69435, 2017
192017
Proteomics in drug development: the dawn of a new era?
M Frantzi, A Latosinska, H Mischak
PROTEOMICS–Clinical Applications 13 (2), 1800087, 2019
182019
Clinical proteomics: Closing the gap from discovery to implementation
M Frantzi, A Latosinska, G Kontostathi, H Mischak
Proteomics 18 (14), 1700463, 2018
142018
Optimized procedure of extraction, purification and proteomic analysis of nuclear proteins from mouse brain
U Jankowska, A Latosinska, B Skupien-Rabian, B Swiderska, ...
Journal of neuroscience methods 261, 1-9, 2016
142016
Recent progress in urinary proteome analysis for prostate cancer diagnosis and management
M Frantzi, A Latosinska, AS Merseburger, H Mischak
Expert review of molecular diagnostics 15 (12), 1539-1554, 2015
142015
Proteome‐based classification of Nonmuscle Invasive Bladder Cancer
R Stroggilos, M Mokou, A Latosinska, M Makridakis, V Lygirou, ...
International journal of cancer 146 (1), 281-294, 2020
132020
Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models
M Frantzi, Z Klimou, M Makridakis, J Zoidakis, A Latosinska, DM Borras, ...
Oncotarget 7 (43), 70750, 2016
132016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20